Tissue factor and thrombin in sickle cell anemia

Thrombosis Research

Volumn 129, Issue SUPPL. 2, 2012, Pages

  Chantrathammachart, Pichika ^a   Pawlinski, Rafal ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

THROMBIN; THROMBOPLASTIN;

BLOOD CLOTTING; BLOOD VESSEL INJURY; HUMAN; INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS; REVIEW; SICKLE CELL ANEMIA; THROMBOSIS;

EID: 84859788016     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2012.02.038     Document Type: Article

References (35)

1. Frenette PS, Atweh GF. Sickle cell disease: old discoveries, new concepts, and future promise. J Clin Invest 2007;117:850-8. (Pubitemid 46556737)
2. Hebbel RP, Vercellotti G, Nath KA. A systems biology consideration of the vasculopathy of sickle cell anemia: the need for multi-modality chemo-prophylaxsis. Cardiovasc Hematol Disord Drug Targets 2009;9:271-92.
3. Rees DC, Williams TN, Gladwin MT. Sickle-cell disease. Lancet 2010;376:2018-31.
4. Ataga KI, Key NS. Hypercoagulability in sickle cell disease: new approaches to an old problem. Hematology Am Soc Hematol Educ Program 2007:91-6.
5. Pawlinski R, Pedersen B, Erlich J, Mackman N. Role of tissue factor in haemostasis, thrombosis, angiogenesis and inflammation: lessons from low tissue factor mice. Thromb Haemost 2004;92:444-50. (Pubitemid 39248000)
6. Key NS, Slungaard A, Dandelet L, Nelson SC, Moertel C, Styles LA, et al. Whole blood tissue factor procoagulant activity is elevated in patientswith sickle cell disease. Blood 1998;91:4216-23. (Pubitemid 28261985)
7. Solovey A, Gui L, Key NS, Hebbel RP. Tissue factor expression by endothelial cells in sickle cell anemia. J Clin Invest 1998;101:1899-904. (Pubitemid 28226109)
8. Shet AS, Aras O, Gupta K, Hass MJ, Rausch DJ, Saba N, et al. Sickle blood contains tissue factor-positive microparticles derived from endothelial cells and monocytes. Blood 2003;102:2678-83. (Pubitemid 37193612)
9. Solovey A, Kollander R, Shet A, Milbauer LC, Choong S, Panoskaltsis-Mortari A, et al. Endothelial cell expression of tissue factor in sickle mice is augmented by hypoxia/reoxygenation and inhibited by lovastatin. Blood 2004;104:840-6. (Pubitemid 38970583)
10. Solovey A, Kollander R, Milbauer LC, Abdulla F, Chen Y, Kelm Jr RJ, et al. Endothelial nitric oxide synthase and nitric oxide regulate endothelial tissue factor expression in vivo in the sickle transgenic mouse. Am J Hematol 2010;85:41-5.
11. Kollander R, Solovey A, Milbauer LC, Abdulla F, Kelm Jr RJ, Hebbel RP. Nuclear factor-kappa B (NFkappaB) component p50 in blood mononuclear cells regulates endothelial tissue factor expression in sickle transgenic mice: implications for the coagulopathy of sickle cell disease. Transl Res 2010;155:170-7.
12. Setty BN, Betal SG, Zhang J, Stuart MJ. Heme induces endothelial tissue factor expression: potential role in hemostatic activation in patients with hemolytic anemia. J Thromb Haemost 2008;6:2202-9.
13. Hebbel RP, Vercellotti GM, Pace BS, Solovey AN, Kollander R, Abanonu CF, et al. The HDAC inhibitors trichostatin A and suberoylanilide hydroxamic acid exhibit multiple modalities of benefit for the vascular pathobiology of sickle transgenic mice. Blood 2010;115:2483-90.
14. Hoppe C, Kuypers F, Larkin S, Hagar W, Vichinsky E, Styles L. A pilot study of the short-term use of simvastatin in sickle cell disease: effects on markers of vascular dysfunction. Br J Haematol 2011;153:655-63.
15. Ataga KI. Hypercoagulability and thrombotic complications in hemolytic anemias. Haematologica 2009;94:1481-4.
16. De Franceschi L, Cappellini MD, Olivieri O. Thrombosis and sickle cell disease. Semin Thromb Hemost 2011;37:226-36.
17. Noubouossie DF, Le PQ, Corazza F, Debaugnies F, Rozen L, Ferster A, et al. Thrombin generation reveals high procoagulant potential in the plasma of sickle cell disease children. Am J Hematol 2011, doi:10.1002/ajh.22206 [Epub ahead of print].
18. Stein PD, Beemath A, Meyers FA, Skaf E, Olson RE. Deep venous thrombosis and pulmonary embolism in hospitalized patients with sickle cell disease. Am J Med 2006;119:897.e7-897.e11.
19. Adedeji MO, Cespedes J, Allen K, Subramony C, Hughson MD. Pulmonary thrombotic arteriopathy in patients with sickle cell disease. Arch Pathol Lab Med 2001;125: 1436-41. (Pubitemid 33070181)
20. Prengler M, Pavlakis SG, Prohovnik I, Adams RJ. Sickle cell disease: the neurological complications. Ann Neurol 2002;51:543-52.
21. Bhalla M, Abboud MR, McLoud TC, Shepard JA, Munden MM, Jackson SM, et al. Acute chest syndrome in sickle cell disease: CT evidence ofmicrovascular occlusion. Radiology 1993;187:45-9. (Pubitemid 23097857)
22. Chantrathammachart P, Key NS, Kirchhofer D, Mackman N, Pawlinski R. Inhibition of tissue factor attenuates coagulation and inflammation in a mouse model of sickle cell disease (Abstracts of the XXIII Congress of the International Society on Thrombosis and Haemostasis). J Thromb Haemost 2011;9:47.
23. Guo Y, Uy T,Wandersee N, Scott PJ, Weiler H, Holzhauer S, et al. The Protein C Pathway inHuman andMurine Sickle Cell Disease: Alterations in Protein C, Thrombomodulin (TM), and Endothelial Protein C Receptor (EPCR) at Baseline and during Acute Vaso-Occlusion (ASH Annual Meeting Abstracts). Blood 2008;112:538.
24. Trudel M, De Paepe ME, Chretien N, Saadane N, Jacmain J, Sorette M, et al. Sickle cell disease of transgenic SAD mice. Blood 1994;84:3189-97. (Pubitemid 24328114)
25. de Franceschi L, Baron A, Scarpa A, Adrie C, Janin A, Barbi S, et al. Inhaled nitric oxide protects transgenic SAD mice from sickle cell disease-specific lung injury induced by hypoxia/reoxygenation. Blood 2003;102:1087-96. (Pubitemid 36917810)
26. Hillery CA, Foster TD, Holzhauer SL, Scott JP, Panepinto JA, Mohandas N, et al. Tissue factor deficiency decreases sickle cell-induced vascular stasis in a hematopoietic stem cell transplant model of murine sickle cell disease (ASH Annual Meeting Abstracts). Blood 2004;104:236.
27. Gavins FN, Russell J, Senchenkova EL, De Almeida Paula L, Damazo AS, Esmon CT, et al. Mechanisms of enhanced thrombus formation in cerebral microvessels of mice expressing hemoglobin-S. Blood 2011;117:4125-33.
28. Polanowska-Grabowska R, Wallace K, Field JJ, Chen L, Marshall MA, Figler R, et al. P-selectin-mediated platelet-neutrophil aggregate formation activates neutrophils in mouse and human sickle cell disease. Arterioscler Thromb Vasc Biol 2010;30: 2392-9.
29. Wallace KL, Marshall MA, Ramos SI, Lannigan JA, Field JJ, Strieter RM, et al. NKT cells mediate pulmonary inflammation and dysfunction in murine sickle cell disease through production of IFN-gammaand CXCR3 chemokines. Blood 2009;114:667-76.
30. Pawlinski R, Pedersen B, Schabbauer G, Tencati M, Holscher T, Boisvert W, et al. Role of tissue factor and protease-activated receptors in a mouse model of endotoxemia. Blood 2004;103:1342-7. (Pubitemid 38168646)
31. Welty-Wolf KE, Carraway MS, Ortel TL, Ghio AJ, Idell S, Egan J, et al. Blockade of tissue factor-factor X binding attenuates sepsis-induced respiratory and renal failure. Am J Physiol Lung Cell Mol Physiol 2006;290:L21-31.
32. Sevastos J, Kennedy SE, Davis DR, Sam M, Peake PW, Charlesworth JA, et al. Tissue factor deficiency and PAR-1 deficiency are protective against renal ischemia reperfusion injury. Blood 2007;109:577-83. (Pubitemid 46105956)
33. Guo YH, Field J, Foster TD, Scott JP, Wandersee N, Hillery CA. Low Molecular Weight Heparin Reduces sVCAM-1 and Lung Congestion In a Murine Model of Sickle Cell Disease (ASH Annual Meeting Abstracts). Blood 2010;116:1635.
34. Matsui NM, Varki A, Embury SH. Heparin inhibits the flow adhesion of sickle red blood cells to P-selectin. Blood 2002;100:3790-6. (Pubitemid 35303953)
35. Qari MH, Aljaouni SK, Alardawi MS, Fatani H, Alsayes FM, Zografos P, et al. Reduction of painful vaso-occlusive crisis of sickle cell anaemia by tinzaparin in a double-blind randomized trial. Thromb Haemost 2007;98:392-6. (Pubitemid 47250243)